Morphic Medical
Developer of an endoscopically delivered temporary duodenal-jejunal bypass liner intended to improve glycemic control and induce weight loss in patients with type 2 diabetes and obesity. The company conducts multi-center clinical studies, maintains a patent portfolio covering gastrointestinal sleeve and anchoring technologies, and pursues regulatory approvals and international commercialization.
Industries
Nr. of Employees
small (1-50)
Morphic Medical
320 Congress Street, 3rd Floor, Boston, MA 02210, USA
Patents
Therapeutic methods involving gastrointestinal implants for administering metabolic agents
US-11179325-B2
View Details
Therapeutic methods involving gastrointestinal implants for administering metabolic agents
US-11179325-B2
View DetailsProducts
Temporary duodenal-jejunal bypass liner (endoscopic intestinal sleeve)
A 60 cm impermeable, flexible sleeve implanted endoscopically in the proximal small intestine to create a physical barrier between intestinal receptors and ingested food, intended to improve glycemic control and induce weight loss during temporary placement (up to ~12 months).
Temporary duodenal-jejunal bypass liner (endoscopic intestinal sleeve)
A 60 cm impermeable, flexible sleeve implanted endoscopically in the proximal small intestine to create a physical barrier between intestinal receptors and ingested food, intended to improve glycemic control and induce weight loss during temporary placement (up to ~12 months).
Services
Organization and management of investigator-led and company-sponsored clinical studies, site coordination, patient screening, monitoring and follow-up visits at specified clinical sites in the US and internationally.
Organization and management of investigator-led and company-sponsored clinical studies, site coordination, patient screening, monitoring and follow-up visits at specified clinical sites in the US and internationally.
Expertise Areas
- Endoscopic device development
- Clinical trial management and multi-center studies
- Regulatory compliance and CE marking
- Gastrointestinal implant and anchoring technologies
Key Technologies
- Endoscopic delivery of intestinal sleeves
- Duodenal-jejunal bypass liner (temporary intestinal sleeve)
- Gastrointestinal anchoring mechanisms
- Fluoropolymer implantable materials
News & Updates
Leadership transition announced; new CEO appointment and commentary on strategic direction and recent regulatory milestone (EU MDR approval mentioned).
Announcement of CE Mark approval under EU MDR for the endoscopic intestinal liner system.
Registry analysis and outcomes describing glycemic and cardiovascular risk improvements across 1,022 patients treated worldwide with a duodenal-jejunal bypass liner.
Meta-analysis reporting effects of duodenal-jejunal bypass liners on glycemic control, weight loss and hormonal changes.
Regulatory approval under the EU Medical Device Regulation (CE marking) for the endoscopic intestinal liner system.
Update to worldwide registry data demonstrating favorable safety and efficacy profile for duodenal-jejunal bypass liner technology.
Leadership transition announced; new CEO appointment and commentary on strategic direction and recent regulatory milestone (EU MDR approval mentioned).
Announcement of CE Mark approval under EU MDR for the endoscopic intestinal liner system.
Registry analysis and outcomes describing glycemic and cardiovascular risk improvements across 1,022 patients treated worldwide with a duodenal-jejunal bypass liner.
Meta-analysis reporting effects of duodenal-jejunal bypass liners on glycemic control, weight loss and hormonal changes.
Regulatory approval under the EU Medical Device Regulation (CE marking) for the endoscopic intestinal liner system.
Update to worldwide registry data demonstrating favorable safety and efficacy profile for duodenal-jejunal bypass liner technology.